Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 11/20 | 0.45 |
| ▸ | BPTF | Q12830 | 1/20 | 0.45 |
| ▸ | IL1B | P01584 | 6/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31000437 | 0.85 | RAD52 (0.40) | RAD52ALDH1A1LMNAMAPTCRHBP | |
| SCHEMBL1814668 | 0.84 | FLT3 (0.45) | KAT2BRAD52ALDH1A1LMNAMAPT | |
| SCHEMBL31203040 | 0.84 | FLT3 (0.45) | KAT2BRAD52ALDH1A1LMNAMAPT | |
| SCHEMBL12676513 | 0.78 | POLB (0.49) | KAT2BBPTF | |
| SCHEMBL31202958 | 0.74 | HTR3E (0.46) | KAT2BRAD52ALDH1A1LMNAMAPT | |
| SCHEMBL31203072 | 0.73 | RAD52 (0.36) | RAD52ALDH1A1LMNAMAPTCRHBP | |
| SCHEMBL10192577 | 0.73 | PRKCZ (0.49) | ALDH1A1LMNAMAPTCRHBPCRHR2 | |
| SCHEMBL19622603 | 0.71 | IL1B (0.43) | KAT2BIL1BNLRP3 | |
| SCHEMBL23177340 | 0.70 | AAK1 (0.42) | KAT2BBPTF | |
| SCHEMBL23177128 | 0.70 | AAK1 (0.42) | KAT2BBPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | KAT2B 212/4885BPTF 3773/4885IL1B 4486/4885 |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | KAT2B 168/4885BPTF 1956/4885IL1B 4491/4885 |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | PAK2, PAK3, PAK4 | KAT2B 250/4885BPTF 4179/4885IL1B 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.